©2022 Australasian Society of Clinical Immunology and Allergy (ASCIA)
ABN 45 615 521 452


Information updates


13 July 2020

Further to updates made in 2019, the ASCIA Chronic Spontaneous Urticaria (CSU) Position Paper and ASCIA CSU Treatment Guidelines for Australia have recently been updated, in response to difficulties in sourcing H2 antagonists.

The following statement has been included on page 16:

Furthermore, H2 antagonists are now difficult to source and the evidence base for efficacy in CSU is weak, so these should no longer be required as a step before allowing prescription of omalizumab.

Changes have also been made on page 19, and to the ASCIA CSU Treatment Guidelines for Australia.

The updated ASCIA CSU Position Paper and Treatment Guidelines are available on the ASCIA website